Coronary artery disease can be clinically silent in patients with type 2 diabetes, remaining undetected until acute events occur. So what approaches and techniques can be taken to aid diagnosis and tailor prevention in this population?
Could an ‘obesity first’ approach, which favors proactive obesity treatment, redefine the management of chronic diseases, such as hypertension, type-2 diabetes, MASLD, CVD, musculoskeletal disorders, and potentially IBD?
Many people with type 2 diabetes do not achieve or maintain tight glycemic control despite the availability of several classes of glucose-lowering agents. What are the prospects for future non-insulin pharmacological approaches?
Explore the integration of semaglutide with medical nutritional therapy for the comprehensive management of obesity, with a focus on the Mediterranean diet and very-low-energy ketogenic therapy.
Liraglutide may reduce recurrent stroke risk versus placebo in people with type 2 diabetes with minor acute ischemic stroke or high-risk transient ischemic attack.
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
What could be causing involuntary and uncontrolled movements in the right arm and leg of a woman with a 25-year history of diabetes and hypertension, beginning shortly after an intramuscular betamethasone injection for shoulder pain?
A man who achieved diabetes remission after gastric bypass presented with hypoglycemic episodes and endogenous hyperinsulinemia. Hypoglycemia resolved and fasting tests normalized when sacubitril/valsartan was discontinued due to worsening renal function.
A woman with abdominal pain was diagnosed with ureteral stones, but her pain persisted despite stent placement. A prior diagnosis of type 2 diabetes led to diabetic ketoacidosis being identified as the cause of the pain.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Diabetic foot ulcers (DFUs) are a common foot issue among diabetic patients, affecting up to 15% of their lifetime. These ulcers are a major cause of lower limb amputation, with 85% of infected foot ulcers leading to amputation. Diabetic foot …
Glomerular diseases are a significant cause of chronic kidney disease (CKD) and kidney failure worldwide, posing a significant burden on healthcare systems [ 1 ]. The prevalence and histopathological patterns of biopsy-proven glomerulopathies …
Mitochondrial dysfunction plays a crucial role in the pathophysiology of Type 1 Diabetes (T1D), as it compromises beta (β)-cell survival and insulin secretion. Autoimmune-driven inflammation disrupts mitochondrial homeostasis and thereby induces …
The pathogenesis of diabetic retinopathy DR is highly complex, and in recent years, increasing attention has been directed toward the role of the gut in its development. Evidence suggests that intestinal barrier dysfunction is a frequent …
Familiarize yourself with current and emerging ketone monitoring systems and the most useful clinical scenarios in which to use them through our podcasts and e-learning modules. Lower the barriers to effective prevention of diabetic ketoacidosis.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills with real cases, vodcasts, and interactive infographics.
Obesity and type 2 diabetes mellitus (T2DM) are two of the most pressing public health challenges worldwide. Over the past four decades, the global prevalence of obesity has risen drastically, with more than 650 million adults classified as obese …
Type 1 diabetes results from chronic autoimmune-mediated destruction of insulin-producing pancreatic beta cells. In recent years, the role of beta cell stress and dysfunction have been recognised as factors contributing to the progression of the …
Obesity is the largest epidemics of non-communicable diseases, and severe obesity is extremely prevalent [ 1 ]. O besity significantly contributes to the development of cancer, cardiovascular diseases, liver diseases, and type 2 diabetes mellitus …
Diabetes autonomic neuropathy (DAN) includes disturbances from the urogenital and gastrointestinal organs, the sudomotor function and cardiovascular autonomic neuropathy (CAN), the latter of which is the most studied form [ 1 ]. CAN symptoms …
Coronary artery disease can be clinically silent in patients with type 2 diabetes, remaining undetected until acute events occur. So what approaches and techniques can be taken to aid diagnosis and tailor prevention in this population?
Many people with type 2 diabetes do not achieve or maintain tight glycemic control despite the availability of several classes of glucose-lowering agents. What are the prospects for future non-insulin pharmacological approaches?
Coronary artery disease can be clinically silent in patients with type 2 diabetes, remaining undetected until acute events occur. So what approaches and techniques can be taken to aid diagnosis and tailor prevention in this population?
A man who achieved diabetes remission after gastric bypass presented with hypoglycemic episodes and endogenous hyperinsulinemia. Hypoglycemia resolved and fasting tests normalized when sacubitril/valsartan was discontinued due to worsening renal function.
